| Autor: |
Philip Bath, Yuan Luo, Anand Srivastava, Andrew M Naidech, Hanyin Wang, Meghan Hutch, Julianne Murphy, James Paparello |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
BMJ Neurology Open, Vol 5, Iss 2 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2632-6140 |
| DOI: |
10.1136/bmjno-2023-000458 |
| Popis: |
Background Acute blood pressure (BP) reduction is standard of care after acute intracerebral haemorrhage (ICH). More acute BP reduction is associated with acute kidney injury (AKI). It is not known if the choice of antihypertensive medications affects the risk of AKI.Methods We analysed data from the ATACH-II clinical trial. AKI was defined by the Kidney Disease: Improving Global Outcomes criteria. We analysed antihypertensive medication from two sources. The first was a case report form that specified the use of labetalol, diltiazem, urapidil or other. We tested the hypothesis that the secondary medication was associated with AKI with χ2 test. Second, we tested the hypotheses the dosage of diltiazem was associated with AKI using Mann-Whitney U test.Results AKI occurred in 109 of 1000 patients (10.9%). A higher proportion of patients with AKI received diltiazem after nicardipine (12 (29%) vs 21 (12%), p=0.03). The 95%ile (90%–99% ile) of administered diltiazem was 18 (0–130) mg in patients with AKI vs 0 (0–30) mg in patients without AKI (p=0.002). There was no apparent confounding by indication for diltiazem use.Conclusions The use of diltiazem, and more diltiazem, was associated with AKI in patients with acute ICH. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
